{"id":391277,"date":"2015-10-22T00:00:00","date_gmt":"2015-10-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcoron0915-biopharma-prostate-cancer-pharmacor-g7-2015\/"},"modified":"2026-04-21T05:29:15","modified_gmt":"2026-04-21T05:29:15","slug":"pcoron0915-biopharma-prostate-cancer-pharmacor-g7-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcoron0915-biopharma-prostate-cancer-pharmacor-g7-2015\/","title":{"rendered":"Prostate Cancer | Pharmacor | G7 | 2015"},"content":{"rendered":"<p><em>Last Updated 22 October 2015<\/em><br \/>\nThe drug treatment of prostate cancer has evolved rapidly over the last few years\u2014the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following the launch of five efficacious therapies since 2010, and the hormonal agents Zytiga (Johnson &#038; Johnson\/Janssen Biotech\/Janssen-Cilag\/AstraZeneca\u2019s abiraterone) and Xtandi (Medivation\/Astellas Pharma\u2019s enzalutamide) compete fiercely in this setting. The prostate cancer drug development pipeline is dynamic, and agents in late-phase development span a wide range of drug classes. The expected launch of several emerging therapies for prostate cancer over 2014-2024 will heighten the competition, and it will be imperative for current and emerging therapies to differentiate and position themselves to maximize clinical and commercial success.<\/p>\n","protected":false},"template":"","class_list":["post-391277","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391277\/revisions"}],"predecessor-version":[{"id":576926,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391277\/revisions\/576926"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}